CPD-N is a cytokine-inducible CPD (carboxypeptidase-D) isoform identified in rat Nb2 T-lymphoma cells. The prototypic CPD (180 kDa) has three CP domains, whereas CPD-N (160 kDa) has an incomplete N-terminal domain I but intact domains II and III. CPD processes polypeptides in the TGN (trans-Golgi network) but the Nb2 CPD-N is nuclear. The present study identified a cryptic exon 1 , downstream of exon 1 of the rat CPD gene, as an alternative transcription start site that encodes the N-terminus of CPD-N. Western-blot analysis showed exclusive synthesis of the 160 kDa CPD-N in rat Nb2 and Nb2-Sp lymphoma cells. Several haematopoietic cell lines including human K562 myeloma, Jurkat T-lymphoma and murine CTLL-2 cytotoxic T-cells express a 160 kDa CPD-immunoreactive protein, whereas mEL4 T-lymphoma cells express the 180 kDa CPD. The CPD-immunoreactive protein in hK562 cells is also nuclear and cytokineinducible. In contrast, MCF-7 breast cancer cells express only the 180 kDa CPD, which is mainly in the TGN. CPD/CPD-N assays using substrate dansyl-L-alanyl-L-arginine show approx. 98 % of CPD-N activity in the Nb2 nucleus, whereas MCF-7 CPD activity is enriched in the post-nuclear 10 000 g pellet. The K m for CPD-N and CPD are 132 + − 30 and 63 + − 9 µM respectively. Specific activity/K m ratios show that dansyl-L-alanyl-L-arginine is a better substrate for CPD-N than for CPD. CPD-N has an optimal pH of 5.6 (due to domain II), whereas CPD has activity peaks at pH 5.6 (domain II) and pH 6.5-7.0 (domain I). CPD and CPD-N are inhibited non-competitively by zinc chelator 1,10-phenanthroline and competitively by peptidomimetic inhibitor DL-2-mercaptomethyl-3-guanidinoethylthiopropanoic acid. The Nb2 CPD-N co-immunoprecipitated with phosphatase PP2A (protein phosphatase 2A) and α4 phosphoprotein. In summary, a cytokine-inducible CPD-N is selectively expressed in several haematopoietic tumour cells. Nuclear CPD-N is enzymatically active and interacts with known partners of CPD.
INTRODUCTION

Rat metallocarboxypeptidase D [CPD (carboxypeptidase D)
] is the only known CP (carboxypeptidase) with multiple CP domains. The digestive CPA and CPB, with an apparent molecular mass of 30 000-40 000 Da, and the peptide-processing CPE and CPM (50 000-60 000 Da) have single CP domains [1] . In contrast, CPD has a molecular mass of 180 000 Da and contains three CPE-like CP domains, a single transmembrane domain and a short C-terminal cytoplasmic tail. The three CP domains (I, II and III) of CPD are believed to be the result of tandem duplications of an ancestral gene and each domain is highly conserved across species [2] . Only domains I and II are enzymatically active [3, 4] ; however, the inactive domain III has retained some of the residues potentially involved in substrate binding, suggesting that it may play a role in the binding and presentation of protein or peptide substrates [5] . The CPD active site uses a glutamic residue and a tightly bound penta-co-ordinated Zn 2+ cofactor to catalyse the cleavage of C-terminal basic amino acid residues [1] . CPD is enzymatically active over a broad pH range and is primarily membrane-bound in the TGN (trans-Golgi network) where it processes polypeptides or prohormones that transit the constitutive secretory pathway [4, [6] [7] [8] . Significant amounts of CPD (∼ 10 %) are also trafficked to and from the plasma membrane [9, 10] . The cell-surface CPD has been shown to cleave extracellular substrates and generate arginine, resulting in enhanced nitric oxide production in macrophages [11] .
Recently, we identified a full-length PRL (prolactin)-inducible cDNA encoding a novel, nuclear-targeted CPD isoform, designated CPD-N, in the rat PRL-dependent Nb2 and PRL-independent Nb2-Sp T-lymphoma cell lines [12] . The full-length rat CPD-N cDNA (3751 bp) has 99.9 % (3582/3583) nucleotide identity with the rat CPD cDNA (4377 bp) [12, 13] . However, the 5 -end of the CPD-N cDNA has 148 unique bases that replace the first 750 bases of the CPD cDNA. Thus the predicted CPD-N protein has a lower molecular mass of 160 000 Da and its primary structure has an incomplete N-terminal CP domain I but intact domains II and III. In CPD-N, truncation of CP domain I includes loss of residues His 139 , Glu 142 and Arg 208 , which are essential for Zn 2+ co-ordination, and the triad N 217 RS 219 , which anchors the carboxylate group of the substrate. Antibodies raised against the conserved C-terminal end of CPD and CPD-N recognize a single immunoreactive band of 160 kDa (i.e. CPD-N) in Nb2 cells and, furthermore, show nuclear distribution of the Nb2 CPD-N [12] . Using isoform-specific primers for RT (reverse transcriptase)-PCR, the CPD-N transcript is detected exclusively in the rat Nb2 and Nb2-Sp lymphoma cells, whereas only the CPD transcript is detected in normal rat brain and lungs [12] . Northern-blot analysis Abbreviations used: Co-IP, co-immunoprecipitation; CPA, carboxypeptidase A; FBS, fetal bovine serum; HS, horse serum; IL-2, interleukin-2; MGTA, DL-2-mercaptomethyl-3-guanidinoethylthiopropanoic acid; OP, 1,10-phenanthroline; PP2A, protein phosphatase 2A; PP2Ac, catalytic subunit of PP2A; PRL, prolactin; TFIIB, transcription factor IIB; TGN, trans-Golgi network.
The nucleotide sequence data reported will appear in GenBank ® , EMBL, DDBJ and GSDB Nucleotide Sequence Databases under the accession numbers NM 012836 for rCPD and AF284830 for rCPD-N. 1 To whom correspondence should be addressed (email ctoo@dal.ca).
shows rapid stimulation of CPD-N expression by PRL or IL-2 (interleukin-2) in the rat lymphoma cells. PRL also stimulates expression of the full-length CPD in human HepG2 hepatoma and MCF-7 breast cancer cell lines. These studies indicate that hormones and cytokines (e.g. PRL and IL-2) can regulate the expression of CPD and CPD-N and, furthermore, suggest that PRL plays a role in regulating CPD/CPD-N processing of polypeptides in the TGN or other protein substrates in the cell nucleus [12] . The present study shows that the CPD-N transcript probably arises from an alternative promoter start site in the rat CPD gene, giving rise to the predicted 160 kDa CPD-N protein in rat Nb2 and Nb2-Sp lymphoma cells. Antibodies raised against the common C-terminal end of CPD/CPD-N also detected a nuclear 160 kDa protein in several mouse and human haematopoietic tumour cells. We also show that nuclear CPD-N in Nb2 cells is enzymatically active and interacts with protein partner(s) of the prototypic CPD.
MATERIALS AND METHODS
Antibodies
Anti-CPD/CPD-N polyclonal antibodies were raised against a common 15 amino acid region in the C-terminal tail of CPD or CPD-N, and the IgG was purified as described previously [12] . The anti-α4 phosphoprotein antibodies used have also been described previously [14] . Polyclonal antibodies directed to TFIIB (transcription factor IIB), glucokinase and horseradish peroxidase-linked secondary goat anti-mouse IgG were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). Monoclonal anti-PP2A (where PP2A stands for protein phosphatase 2A; catalytic subunit) was purchased from Transduction Laboratories (Mississauga, ON, Canada). Secondary donkey antirabbit IgG was obtained from Amersham Biosciences (Baie d'Urfé, QC, Canada).
Cell culture
Suspension cultures of the PRL-dependent rat Nb2-11C (Nb2) lymphoma cell line were routinely maintained in Fischer's medium (Sigma, Oakville, ON, Canada) for leukaemic cells containing 10 % (v/v) FBS (fetal bovine serum; as a source of lactogens) and 10 % lactogen-free HS (horse serum) as described previously [15] . For growth arrest, Nb2 cells were cultured in the medium containing 10 % HS alone for 18-24 h. Nb2 cell growth is also stimulated by IL-2; thus, the HS was also IL-2-free. The PRL-independent rat Nb2-Sp cell line was maintained in 10 % HS-Fischer's medium. Human MCF-7 breast cancer cell line, Jurkat T-leukaemic cell line and K562 myeloma cell line were all cultured in Dulbecco's modified Eagle's medium containing 10 % FBS. Mouse EL4 T-cell lymphoma and CTLL-2 cytotoxic T-cells were maintained in RPMI 1640 with 10 % FBS; CTLL-2 cells are IL-2-dependent and also received 20 ng/ml IL-2. MCF-7 and K562 cells express receptors for PRL and IL-2 respectively. Quiescent cells were obtained by culturing cells in 10 % HS (PRLand IL-2-free) for 18-24 h before hormone treatment.
Subcellular fractionation and Western-blot analysis
For whole cell lysates, cells [(10-20 6 ] were harvested at 200 g for 5 min, lysed in RIPA buffer (without detergent) for 30 min on ice and further disrupted by gentle passage through a 21-gauge needle. Whole cell homogenates, nuclear (700 g pellet, 5 min), organelle (10 000 g pellet, 25 min), microsomal (100 000 g pellet, 60 min) and cytosolic (100 000 g supernatant, 60 min) fractions were obtained. Protein concentrations were determined, Triton X-100 was added to a final concentration of 0.1 % (v/v) and samples were stored at − 20
• C. SDS/PAGE was performed using 10-30 µg of protein/ lane, representing approx. 15 % of the total protein in each fraction.
Western blotting was performed with the following primary antibodies: anti-CPD/CPD-N (15 µg/ml IgG), anti-TFIIB (1 µg/ ml) and anti-glucokinase (2 µg/ml). Horseradish peroxidaseconjugated secondary antibodies, donkey anti-rabbit IgG and goat anti-mouse IgG were used at 1:5000 and 1:1500 dilution respectively. Immunoreactive signals were detected with Super Signal ULTRA kit (Pierce, Rockford, IL, U.S.A.).
Co-IP (co-immunoprecipitation)
Cells were harvested with RIPA buffer and precleared with Protein A/G-agarose (Santa Cruz Biotechnology) at 4
• C for 1 h. Samples were then centrifuged at 800 g for 5 min at 4
• C and 1.0 µg of primary antibody was added to the supernatant. Protein A/Gagarose was added 1 h later and the samples were rocked overnight at 4
• C. The pellet was again collected by centrifugation at 800 g for 5 min and washed twice with 1 ml of cold PBS. SDS/PAGE sample buffer was added for Western blotting.
Immunofluorescent confocal microscopy
Suspension cultures of K562 cells were cytospun on to silinized microscope slides, dried in cold acetone, fixed in 1 % paraformaldehyde and permeabilized in 0.1 % Triton X-100 as described previously [12] . The permeabilized cells were incubated with the primary antibody (1:10 of 4 mg/ml anti-CPD/CPD-N IgG in 0.1 % BSA/PBS) for 1 h at room temperature (18 • C) and washed three times in PBS before incubation with secondary antibody (1:50 of AlexaFluor 488 goat anti-rabbit IgG conjugate) for 1 h in the dark. After three PBS washes, the cells were incubated with propidium iodide (50 ng/ml in 0.1 % BSA) for 10 min. After a final series of PBS washes, a drop of Citifluor-glycerol/PBS AF1 solution (Marivac Halifax, Halifax, NS, Canada) was added and the slides were mounted with coverslips. Immunofluorescence was detected by confocal microscopy at × 100 magnification. MCF-7 cells were cultured on coverslips and were similarly processed as the K562 cells. At the final stage, a drop of Citifluor was added to each coverslip that was then mounted on a microscope slide.
Preparation of the dansyl-L-alanyl-L-arginine substrate
The CPD substrate dansyl-L-alanyl-L-arginine was synthesized by reacting dansyl chloride with the dipeptide, alaninearginine as described previously [16] [17] [18] . Substrate purity was confirmed using TLC on 1 mm silica with chloroform/methanol (1:1) and a single fluorescent spot (R F = 0.7) was detected by a Varian Cary Eclipse fluorescence spectrophotometer, indicating that the material was > 99 % pure.
CPD/CPD-N enzyme assay
Nb2 and MCF-7 cells [(10-20) × 10 6 ] were homogenized with a 21-gauge needle in 0.1 M sodium acetate buffer (pH 5.6). Total cell lysates or subcellular fractions were prepared (see above) and then Triton X-100 was added to each fraction to give a final concentration of 0.1 % (v/v). Samples were stored at − 20
• C until further analysis. CPD activity was determined using an endpoint fluorescence assay as described previously [7, 18] . Briefly, the icecold enzyme sample (60-80 ng of protein/µl in a total volume of 50 µl) was preincubated with 150 µl of 0.1 M sodium acetate buffer (pH 5.6) at 37
• C for 5 min. The assay was initiated by the addition of pre-equilibrated (37
• C) dansyl-L-alanyl-L-arginine substrate (in 50 µl of 0.1 M sodium acetate buffer, pH 5.6). After a 37
• C incubation (6 min for CPD-N and 10 min for CPD), the reaction was terminated by the addition of 150 µl of 1 M citric acid and the sample was placed on ice. The product dansyl-L-alanine was separated from the more hydrophilic substrate, dansyl-L-alanyl-L-arginine, by extraction with chloroform. Fluorescence in the chloroform layer was measured relative to a chloroform blank at 340 nm excitation wavelength and 495 nm emission. Dansyl-L-alanine (Tokyo Chemical Industry America, Portland, OR, U.S.A.) was used at various concentrations to construct a standard curve for each assay to correct for the perturbations in extraction efficiency. The inhibitors used were MGTA (DL-2-mercaptomethyl-3-guanidinoethylthiopropanoic acid; Calbiochem, La Jolla, CA, U.S.A.) and OP (1,10-phenanthroline; Sigma). For pH profile experiments, 0.1 M NaOAc was used for pH 3.5-5.6 and 0.1 M sodium phosphate (NaH 2 PO 4 /Na 2 HPO 4 ) was used for pH 6.0-7.5. CP activity was determined as the difference in activity in the presence or absence of 10 µM MGTA. Specific activity SA was calculated as V max (µmol/min = unit) per mg of protein (i.e. SA = unit/mg of protein).
RESULTS
Analysis of rat CPD-N and CPD cDNAs
The rat genome database [NCBI (National Center for Biotechnology Information)] was used to analyse the rat CPD and CPD-N cDNAs. Our analysis showed that 750 bases specific to the 5 -end of CPD cDNA were lost in the CPD-N cDNA and 148 additional bases unique to the 5 -end of the CPD-N cDNA were added [12] . These alterations are probably caused by an alternative start site resulting in transcription initiation at exon 1 , downstream of exon 1 (Figure 1 ). This would also result in the loss of any N-terminal signal peptide. In CPD, the signal peptide is responsible for both the trafficking of CPD into the lumen of the endoplasmic reticulum and for the insertion of CPD into the membrane of the TGN [1, 5] . The absence of a signal peptide from CPD-N may dictate its alternative distribution in the cell nucleus.
Expression of CPD/CPD-N in haematopoietic cells
The full-length rat CPD cDNA has 92 and 83 % nucleotide identity with the mouse and human CPD cDNAs respectively. CPD-N-specific primers were initially designed for the unique 5 -end of the Nb2 CPD-N cDNA to yield a 264 bp PCR product [12] . BLAST analysis showed that the forward and reverse primers annealed to regions within the putative exon 1 and exon 2 of the rat CPD genomic sequence respectively (Figure 2A) . Although BLAST and Amplify 1.0 analyses revealed potential annealing sites in similar regions in the mouse and human CPD genomic sequences, the nucleotide identity was not fully conserved (Figure 2B) . Furthermore, no open reading frame that would produce a 160 kDa CPD-N-like protein was identified in the corresponding regions of the mouse and human CPD genes. (A) Arrowheads show the annealing sites of the Nb2 CPD-N-specific primers which yielded the 264 bp PCR product previously reported [12] . (B) BLAST analyses showed 100 % base identity of the forward and reverse primers with the annealing sites in the rat CPD gene, but less than 100 % identity with corresponding regions in the mouse and human CPD genes.
Therefore Western-blot analysis was performed using CPD/ CPD-N-specific antibodies to determine if the 160 kDa and/or 180 kDa CPD-immunoreactive protein was expressed in murine and human lymphoid tumour cells lines. Human MCF-7 breast cancer cells were used for comparison since we have shown by RT-PCR, using hCPD-specific primers, that PRL stimulated CPD expression (but not CPD-N) in these cells [12] . Figure 3 shows exclusive synthesis of the 180 kDa CPD in MCF-7 cells and the 160 kDa CPD-N in Nb2 and Nb2-Sp cells (Figures 3A and 3B) . A 160 kDa immunoreactive band was detected in human K562 myeloid or Jurkat T-leukaemic cells (Figures 3B and 3C) . A single immunoreactive band of 180 or 160 kDa was detected in murine EL4 T-lymphoma and CTLL-2 cytotoxic T-cells respectively ( Figure 3C ). It is possible that the 160 kDa immunoreactive band is a spliced product from an unidentified start site in the human or mouse CPD gene. However, we cannot rule out the possibility that this smaller protein detected in the human and mouse samples was processed post-translationally from the mature 180 kDa CPD.
Localization of CPD-N
Previously, we demonstrated nuclear distribution of 160 kDa CPD-N in Nb2 cells using immunofluorescence confocal microscopy [12] . Here we examined the subcellular distribution of the 160 kDa protein in K562 myeloma cells and compared it with the distribution of the 180 kDa CPD in MCF-7 breast cancer cells. Figure 4 (A) reveals that CPD has a perinuclear distribution in MCF-7 cells, consistent with its reported predominance in the TGN [9, 19] . However, some punctate nuclear staining was also observed. In contrast, immunofluorescence of the 160 kDa protein was detected in both the nucleus of quiescent K562 cells and in the cytosol after treatment with IL-2 for 24 h (Figure 4B) , further supporting the presence of a nuclear CPD-N immunoreactive protein in other lymphoid tumour cells. The appearance of immunofluorescence in the cytosol is consistent with IL-2 stimulation of CPD-N protein synthesis.
Co-IP of CPD-N protein partners
The serine/threonine phosphatase PP2A is known to bind to the cytoplasmic tail of CPD as a trimeric complex consisting of A (regulatory), B (variable) and C (catalytic) subunits [20] . Co-IP analysis showed that CPD-N in Nb2 cells interacted with PP2Ac (catalytic subunit of PP2A) ( Figure 5A ), demonstrating that the protein-protein interactions characteristic of the C-terminus of CPD are preserved in the CPD-N isoform. The different intensities of the immunoreactive bands corresponding to CPD-N and PP2Ac ( Figure 5A ) suggested that most of the CPD-N molecules were bound to PP2Ac but only a fraction of the PP2Ac molecules interacted with CPD-N.
PP2Ac is a known partner of α4 phosphoprotein [14, 21] , a protein component of the mTOR (mammalian target of rapamycin) pathway that regulates protein translation [22] . Both PP2Ac and α4 phosphoprotein are found predominantly in the Nb2 cell nucleus [14] . Thus it was not surprising to find an interaction of CPD-N with the α4 phosphoprotein in the Nb2 cells ( Figure 5B, left panel) . However, the reverse Co-IP using anti-α4 antibodies precipitated PP2Ac only but not CPD-N ( Figure 5B , right panel), suggesting that α4 might be sequestered in the CPD-N-α4-PP2Ac complex and not available to the anti-α4 antibodies.
Kinetic properties of CPD-N and CPD
To measure CP enzymatic activities, Nb2 and MCF-7 cells were used as the sources for CPD-N and CPD respectively. Subcellular fractionation showed CPD-like activity in Nb2 cells that was almost entirely (∼ 98 %) nuclear ( Figure 6A ). In contrast, CPD activity in MCF-7 cells was enriched in the post-nuclear fraction (10 000 g; Figure 6A , PNO) but some activity was also detected in the nuclear, microsomal and cytosolic fractions ( Figure 6A ).
Western-blot analysis detected abundant CPD-N (160 kDa) in the Nb2 cell nucleus ( Figure 6B ), which is in agreement with the cellular distribution indicated by enzymatic activity ( Figure 6A ). The distribution of CPD activity in MCF-7 cells is also consistent with the nuclear and perinuclear (i.e. TGN) staining for CPD ( Figure 4A ) and the detection of the CPD protein in the TGN and membrane fractions reported by others [9, 19, 23] . The detection of cytosolic glucokinase and a nuclear TFIIB confirmed fraction integrity ( Figure 6B ).
The kinetic properties of CPD-N and CPD were further examined using the Nb2 nuclear and MCF-7 PNO fractions respectively. Michaelis-Menten and Lineweaver-Burk plots for CPD-N ( Figure 7 ) and CPD (results not shown) were used to determine their apparent K m and V max values ( Table 1 ). The apparent K m values were 132 + − 30 and 63 + − 9 µM for CPD-N and CPD respectively, suggesting that CPD binds dansyl-L-alanyl-Larginine with twice the affinity exhibited by CPD-N.
To characterize further the two isoforms, inhibition studies were conducted using the potent peptidomimetic inhibitor MGTA and the Zn 2+ -chelator OP. MGTA is a strong competitive inhibitor of CPD at nM concentrations, whereas OP is a less potent non-competitive inhibitor and is typically used at µM concentrations [4] . Lineweaver-Burk plots for the inhibition of CPD-N in the presence of MGTA ( Figure 8A ) or OP ( Figure 9A ) indicated competitive inhibition by MGTA and non-competitive inhibition by OP. Furthermore, plots of K m /V max versus inhibitor concentrations were used to determine the inhibition constants (K i ) of MGTA ( Figure 8B ) and OP ( Figure 9B ). In addition, MGTA and OP inhibition of CPD was determined similarly (results not shown). Table 2 shows that the K i values for the inhibition of CPD-N by MGTA and OP are approx. 5-fold less than those for CPD. Thus both CPD and CPD-N exhibited competitive inhibition with MGTA and non-competitive inhibition with OP.
Optimal pH of CPD and CPD-N
CPD is believed to process polypeptides or prohormones as they transit the TGN-endosomal pathway and is active over a broad pH range (pH 5-7), presumably permitting the enzyme to function at the varying pH values encountered along the secretory pathway [1] . CP domain I is optimally active at a neutral pH, whereas domain II has an optimum pH of 5.6 [4] . Since CPD-N lacks a functional domain I, it was expected to be active only in the lower pH range. Indeed, Figure 10 confirms that CPD-N has a single optimum pH of 5.6, whereas CPD exhibits optimal activity at pH 5.6 and for pH 6.5-7.0.
DISCUSSION
Our studies showed that, like the prototypic 180 kDa rat CPD, the nuclear 160 kDa CPD-N is a catalytically active enzyme. Cytokine stimulation of CPD-N expression suggests a role for PRL and IL-2 in polypeptide processing in the nucleus of haematopoietic cells. We originally identified CPD-N as a PRL-inducible cDNA in the rat Nb2 lymphoma cell line with 99.9 % nucleotide identity with the rat CPD cDNA [12] . However, the 5 -end of the fulllength CPD-N cDNA appeared to be truncated when compared with the CPD cDNA. The origin of the CPD-N transcript was not known. Analysis of the rat genome now suggests that the CPD gene is transcribed at an alternative start site downstream of exon 1 to produce the CPD-N transcript (Figure 1 ). Exon 1 of the CPD gene encodes the CP domain I but the downstream cryptic exon 1 , demarcated by classical intron-exon splice sequences (agGT-AGgt), encodes the N-terminus of CPD-N. A 160 kDa CPD-N-like protein appears to be frequently expressed in a number of haematopoietic tumour cells. An NCBI EST (expressed sequence tag) database search failed to identify the CPD-N cDNA sequence in normal mammalian tissues, suggesting that its expression may be restricted by cell lineage or tumour phenotype. Furthermore, unlike most vertebrate mRNAs, which use the Kozak consensus sequence (gcc)a/gccATGg for initiation of translation [24] , translation of the Nb2 CPD-N mRNA is predicted to occur at cagATGa to yield the 160 kDa gene product (Figure 1) . However, there are many examples of non-conventional Kozak sequences (http://www.changbioscience.com/primo/human.html), including usage of the same cagATGa sequence in translation initiation of human forkhead transcription factor FREAC2 (AF084938), forkhead FOXF2 (NM001452), IL-11 receptor α-chain (BC003110) and synapsin IIb (U40215).
Alternative exon usage has been reported for other CP-like enzymes. When the Drosophila melanogaster silver (svr) gene was first cloned, it was identified to encode multiple preproteinprocessing carboxypeptidases similar to human CPE, CPM, and CPN [25] . The Drosophila svr gene has eight exons and actually encodes a 'long' form of a CPD-like protein that has three CP-like domains, followed by a transmembrane domain and a cytosolic tail [26] . The svr gene has three alternatively spliced first exons (exons 1A, 1B and 1C), and use of either exon 1A or 1B results in (A) Nb2 and MCF-7 fractions were used for CPD-N and CPD assays respectively. Enzyme activity was determined as the difference in activity measured in the presence or absence of the specific CPD inhibitor MGTA as described in the Materials and methods section. H, whole cell homogenate; NUC, nucleus, 700 g pellet; PNO, post-nuclear, 10 000 g pellet; MS, microsomes, 100 000 g pellet; CYT, cytosol, 100 000 g supernatant. CPD-N (Nb2) activity was predominantly in the NUC fraction, whereas CPD (MCF-7) activity was mainly in the PNO and MS fractions. ND, not significant. . A similar kinetics analysis was performed for the MCF-7 CPD using the 10 000 g pellet (15 µg of protein/assay) (see Table 1 ).
expression of 'long' CPD-like proteins with different N-terminal domains (either 1A or 1B). In addition, 'short' forms of the enzyme are produced that only have the first domain (1A or 1B) but not domain 2 or 3. The N-terminal regions of the proteins encoded by the first ATGs in exons 1A and 1B are predicted to encode signal peptides, whereas exon 1C encodes a protein that Table 2 ).
lacks a signal peptide but which has a truncated CP-like domain. When individual domains of the Drosophila CPD were expressed, domains 1B and 2, but not 1A, were found to be enzymatically active, cleaving substrates with a C-terminal arginine or lysine residue. Domain 1B was more active at neutral pH and greatly preferred C-terminal arginine to lysine, whereas domain 2 was more active at pH 5-6 and slightly preferred C-terminal lysine to arginine. These properties of the Drosophila domains 1B and 2 are similar to those of domains 1 and 2 of the CPD in duck [4] and mammals [8, 13, 27] . The conservation of these enzymatic properties (optimum pH and substrate specificity) of the first two domains has been suggested to be essential to CPD function [26] . On the other hand, the nuclear CPD-N is enzymatically active, indicating that CPD-like enzymes without an intact domain I are functional but, due to its domain II, has optimal activity at a pH of approx. 5.6. The full-length CPD has three CP enzyme homology domains with amino acid residues from about 86-381 making up domain I. Table 2 ). The N-terminal 249 residues in CPD are absent from CPD-N and their absence not only results in an inactive domain I but also in loss of the signal peptide in CPD-N. In the full-length CPD, the signal peptide and the C-terminal transmembrane domain are believed to interact co-operatively to form a hydrophobic transmembrane region that permits CPD to insert into the TGN membrane [9, 19, 23] . The absence of a signal peptide in the 160 kDa CPD-N may account for its diffuse distribution, not in the TGN, but within the nucleus of Nb2 cells [12] and K562 cells (Figure 4) . Novikova et al. [4] previously reported that domain I of CPD (optimum pH of 6.5-7.0) had a greater affinity for substrates with a C-terminal arginine residue, whereas domain II (optimum pH of 5.6) preferentially bound substrates with a C-terminal lysine residue. This substrate specificity is consistent with our observation that CPD-N, with only domain II, exhibited a reduced affinity (132 + − 30 µM) for dansyl-L-alanyl-L-arginine relative to CPD with its domain I (63 + − 9 µM). However, comparison of the specific activity/K m ratios reveals that dansyl-L-alanyl-Larginine is a better substrate for CPD-N than CPD. Our studies also confirmed that CPD (in MCF-7 cells) has two optimum pH values at 5.6 and 6.5-7.0, due to its domains II and I respectively, whereas CPD-N has only a single optimum pH at 5.6 due to domain II. The finding that CPD-N has an acidic optimum pH raises the question of whether it is active in the cell nucleus. Nuclear enzymes that display acidic optimum pH in vitro have been reported. These include a family of nucleases, exemplified by DNase II, that are implicated in apoptotic DNA digestion [28, 29] and a recently characterized acidic nuclease/intra-cyclobutylpyrimidine-dimer-DNA phosphodiesterase that may function in apoptotic DNA digestion as well as in metabolism of cyclobutyl pyrimidine primers in UV-irradiated cells [30] . The broad pH range of CPD is believed to facilitate the processing of polypeptides transiting the length of the secretory pathway within the TGN and immature vesicles [4, [6] [7] [8] . Although the physiological substrate(s) of CPD-N is not yet known, its pH-activity profile suggests that its potential substrate(s) may contain C-terminal arginine residues.
CPD is known to undergo post-translational modification, including palmitoylation and phosphorylation [10, 20, 31] . The cytoplasmic tail of CPD can be phosphorylated by purified protein kinase A, protein kinase C and CK2 [20] . The CPD tail also interacts with PP2A [20] . The binding of the CPD tail does not influence the catalytic activity of PP2A, but PP2A is involved in the trafficking of CPD from the TGN to the plasma membrane [20] . The α4 phosphoprotein is a known protein partner of PP2Ac [14, 21] and is implicated as a positive regulator of PP2A activity [32] . The nuclear substrates for CPD-N are not known, but our demonstration of a CPD-N-α4-PP2Ac complex implicates a potential role for α4-PP2Ac in CPD-N action.
The hCPD gene and its promoter (a total of ∼ 88.3 kb) were recently characterized [33] . The hCPD gene contains 21 introns and has multiple transcription start sites. The promoter region of the hCPD gene lacks a TATA box but contains three GC boxes and the binding site for the transcription factor Sp1 and a putative site for nuclear factor κB. Timblin et al. [33] pointed out that Sp1 is essential for regulating the expression of several myeloidspecific genes, for example, through Sp1 binding to the promoters of CD11B [34] and the proto-oncogene c-fes [35] . Sp1 is also associated with PRL-responsive genes in lymphoid tumour cells [36, 37] . Since the rat CPD-N and CPD transcripts are derived from the same CPD gene, Sp1 probably plays a role in the PRLinducible expression of both these transcripts. In future studies, the potential interaction between Sp1 and the CPD/CPD-N gene promoter will be examined by chromatin immunoprecipitation assays.
In summary, we have demonstrated that cytokine-inducible CPD-N is expressed in several haematopoietic tumour cell lines. Specific protein-protein interaction at the C-terminal end of CPD, such as with PP2Ac, is preserved in CPD-N. In addition, we have demonstrated that CPD-N is a catalytically active metallocarboxypeptidase that acts optimally at pH 5.6 due to its intact domain II. In contrast, CPD, with intact domains I and II, acts over a much broader pH range.
